Literature DB >> 32381561

Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.

Maximilian F Konig1, Alfred Hj Kim2,3,4, Marc H Scheetz5,6, Elizabeth R Graef7, Jean W Liew8, Julia Simard9, Pedro M Machado10,11,12, Milena Gianfrancesco13, Jinoos Yazdany13, Daman Langguth14, Philip C Robinson15.   

Abstract

Entities:  

Keywords:  epidemiology; hydroxychloroquine; lupus erythematosus, systemic; pharmacokinetics

Mesh：

Substances：

Year:  2020        PMID： 32381561      PMCID： PMC8258626          DOI： 10.1136/annrheumdis-2020-217690

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  15 in total

1.  Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice.

Authors:  Dale L Barnard; Craig W Day; Kevin Bailey; Matthew Heiner; Robert Montgomery; Larry Lauridsen; Paul K S Chan; Robert W Sidwell
Journal:  Antivir Chem Chemother       Date:  2006

2.  Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

Authors:  Julie Dyall; Christopher M Coleman; Brit J Hart; Thiagarajan Venkataraman; Michael R Holbrook; Jason Kindrachuk; Reed F Johnson; Gene G Olinger; Peter B Jahrling; Monique Laidlaw; Lisa M Johansen; Calli M Lear-Rooney; Pamela J Glass; Lisa E Hensley; Matthew B Frieman
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

3.  Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.

Authors:  Michelle Petri; Marwa Elkhalifa; Jessica Li; Laurence S Magder; Daniel W Goldman
Journal:  Arthritis Rheumatol       Date:  2020-01-07       Impact factor: 10.995

4.  Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.

Authors:  C R Rayner; C C Bulik; M A Kamal; D K Reynolds; S Toovey; J P Hammel; P F Smith; S M Bhavnani; S A Van Wart; P G Ambrose; A Forrest
Journal:  Antimicrob Agents Chemother       Date:  2013-05-13       Impact factor: 5.191

Review 5.  Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.

Authors:  Julie Dyall; Robin Gross; Jason Kindrachuk; Reed F Johnson; Gene G Olinger; Lisa E Hensley; Matthew B Frieman; Peter B Jahrling
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

6.  SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  Ann Rheum Dis       Date:  2020-04-15       Impact factor: 19.103

7.  Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.

Authors:  Alexis Mathian; Matthieu Mahevas; Julien Rohmer; Mathilde Roumier; Fleur Cohen-Aubart; Blanca Amador-Borrero; Audrey Barrelet; Cecile Chauvet; Thibaud Chazal; Michel Delahousse; Mathilde Devaux; Romain Euvrard; Jehane Fadlallah; Nans Florens; Julien Haroche; Miguel Hié; Laurent Juillard; Raphael Lhote; Thibault Maillet; Gaelle Richard-Colmant; Jean Baptiste Palluy; Micheline Pha; Laurent Perard; Philippe Remy; Etienne Rivière; Damien Sène; Pascal Sève; Capucine Morélot-Panzini; Jean-François Viallard; Jean-Simon Virot; Neila Benameur; Noël Zahr; Hans Yssel; Bertrand Godeau; Zahir Amoura
Journal:  Ann Rheum Dis       Date:  2020-04-24       Impact factor: 27.973

8.  Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection.

Authors:  Samuel L M Arnold; Frederick Buckner
Journal:  Clin Transl Sci       Date:  2020-04-08       Impact factor: 4.689

9.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Authors:  Xueting Yao; Fei Ye; Miao Zhang; Cheng Cui; Baoying Huang; Peihua Niu; Xu Liu; Li Zhao; Erdan Dong; Chunli Song; Siyan Zhan; Roujian Lu; Haiyan Li; Wenjie Tan; Dongyang Liu
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

10.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.

Authors:  Jia Liu; Ruiyuan Cao; Mingyue Xu; Xi Wang; Huanyu Zhang; Hengrui Hu; Yufeng Li; Zhihong Hu; Wu Zhong; Manli Wang
Journal:  Cell Discov       Date:  2020-03-18       Impact factor: 10.849
View more
  27 in total

1.  The effects of COVID-19 infection on the mortality of patients receiving rituximab therapy.

Authors:  Ali Ekin; Belkıs Nihan Coskun; Ediz Dalkilic; Yavuz Pehlivan
Journal:  Ir J Med Sci       Date:  2022-10-19       Impact factor: 2.089

Review 2.  Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation.

Authors:  Isabelle Amigues; Alexander H Pearlman; Aarat Patel; Pankti Reid; Philip C Robinson; Rashmi Sinha; Alfred Hj Kim; Taryn Youngstein; Arundathi Jayatilleke; Maximilian Konig
Journal:  Expert Rev Clin Immunol       Date:  2020-11-25       Impact factor: 4.473

3.  Response to: 'Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by Singer et al.

Authors:  Alfred Hyoungju Kim; Jeffrey A Sparks; Manuel Francisco Ugarte-Gil; Maximilian F Konig; Peter Korsten; Francis Berenbaum
Journal:  Ann Rheum Dis       Date:  2020-08-05       Impact factor: 19.103

Review 4.  COVID-19 therapeutics: Challenges and directions for the future.

Authors:  Philip C Robinson; David F L Liew; Helen L Tanner; John R Grainger; Raymond A Dwek; Ronald B Reisler; Lawrence Steinman; Marc Feldmann; Ling-Pei Ho; Tracy Hussell; Paul Moss; Duncan Richards; Nicole Zitzmann
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-06       Impact factor: 12.779

5.  Frequency and severity of COVID-19 in patients with various rheumatic diseases treated regularly with colchicine or hydroxychloroquine.

Authors:  Mert Oztas; Murat Bektas; Ilker Karacan; Numune Aliyeva; Ayten Dag; Sarvan Aghamuradov; Selim Berke Cevirgen; Selma Sari; Murat Bolayirli; Gunay Can; Gulen Hatemi; Emire Seyahi; Huri Ozdogan; Ahmet Gul; Serdal Ugurlu
Journal:  J Med Virol       Date:  2022-03-29       Impact factor: 20.693

6.  Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon et al.

Authors:  Maximilian F Konig; Milena Gianfrancesco; Jinoos Yazdany; Philip C Robinson
Journal:  Ann Rheum Dis       Date:  2020-05-31       Impact factor: 27.973

7.  Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.

Authors:  Andrea Cortegiani; Mariachiara Ippolito; Giulia Ingoglia; Pasquale Iozzo; Antonino Giarratano; Sharon Einav
Journal:  J Crit Care       Date:  2020-07-11       Impact factor: 3.425

8.  Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.

Authors:  Milena Gianfrancesco; Kimme L Hyrich; Jinoos Yazdany; Pedro M Machado; Philip C Robinson; Sarah Al-Adely; Loreto Carmona; Maria I Danila; Laure Gossec; Zara Izadi; Lindsay Jacobsohn; Patricia Katz; Saskia Lawson-Tovey; Elsa F Mateus; Stephanie Rush; Gabriela Schmajuk; Julia Simard; Anja Strangfeld; Laura Trupin; Katherine D Wysham; Suleman Bhana; Wendy Costello; Rebecca Grainger; Jonathan S Hausmann; Jean W Liew; Emily Sirotich; Paul Sufka; Zachary S Wallace
Journal:  Ann Rheum Dis       Date:  2020-05-29       Impact factor: 19.103

9.  Cutaneous lupus erythematosus patients in a high-epidemic COVID-19 area, Bergamo, Italy.

Authors:  Pamela Vezzoli; Marco Di Mercurio; Andrea Carugno; Daniele Mario Gambini; Elisa Robustelli Test; Gianlorenzo Imberti; Angelo Francesco Castagna; Paolo Sena
Journal:  Dermatol Ther       Date:  2020-07-03       Impact factor: 3.858

Review 10.  Complexities of diagnosis and management of COVID-19 in autoimmune diseases: Potential benefits and detriments of immunosuppression.

Authors:  Tsvetoslav Georgiev; Alexander Krasimirov Angelov
Journal:  World J Clin Cases       Date:  2020-09-06       Impact factor: 1.337
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.